法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭的临床疗效

目的探讨法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭的临床疗效及安全性。方法选取100例慢性充血性心力衰竭患者为研究对象,按随机数字表法分为观察组和对照组,各50例。对照组患者给予厄贝沙坦治疗,观察组患者给予法莫替丁联合厄贝沙坦治疗;对比分析两组患者临床治疗效果、治疗前后超声心动图相关指标和血压的改善情况,以及不良反应发生情况。结果观察组治疗总有效率高于对照组(P0.05);治疗后的左心室舒张末期内径(LVED)、左心室收缩末期内径(LVES)、舒张压和收缩压均低于对照组的(P0.05);治疗后的左心室射血分数(LVEF)高于对照组(P0.05)。结论法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭,安全性好,临床治疗效果好,值得临床应用。     

厄贝沙坦联合美托洛尔治疗心力衰竭38例疗效观察

目的观察厄贝沙坦（安博维）联合美托洛尔（倍他乐克）治疗充血性心力衰竭（CHF）的临床效果。方法将68例充血性心力衰竭患者按随机数分配法分成两组。治疗组38例,除常规治疗外,口服厄贝沙坦和美托洛尔,美托洛尔小剂量开始,逐渐增量。对照组30例,给予常规抗心衰治疗。结果治疗组疗效优于对照组（u=3.564,P=0.000）。结论厄贝沙坦与美托洛尔联合应用治疗CHF简单易行,安全有效,对伴有心率增快和血压升高的CHF,更为适用。     

厄贝沙坦联合辛伐他汀治疗充血性心力衰竭的疗效

目的：探究厄贝沙坦联合辛伐他汀对充血性心力衰竭（CHF）的临床疗效.方法：选择在我院接受治疗的CHF患者286例,按随机数字表法均分为联合用药组（厄贝沙坦联合辛伐他汀治疗）和辛伐他汀组（辛伐他汀治疗）,治疗3个月,随访两组的疗效.结果：联合用药组总有效率显著高于辛伐他汀组（72.73％比48.95％,P＜0.01）;治疗后与辛伐他汀组比较,联合用药组左室射血分数[（33.6±4.5）％比（45.6±6.8）％]明显提高,左室舒张末期内径[（57.4±5.6） mm比（60.9±5.4） mm]、收缩末期内径[（46.7±3.2） mm比（49.5±3.5）mm],E/A比值[（0.84±0.12）比（1.45±0.31）]显著增大（P＜0.05～＜0.01）;联合用药组BNP水平在治疗3个月时显著低于辛伐他汀组[（790.8±91.1） pg/ml比（970.4±99.2） pg/ml,P＜0.05～＜0.01].结论：厄贝沙坦联合辛伐他汀治疗充血性心力衰竭疗效高,可以显著改善心功能.     

国产厄贝沙坦治疗充血性心力衰竭的疗效观察

目的:观察国产厄贝沙坦治疗充血性心力衰竭(CHF)的临床疗效。方法:25例CHF患者,停用血管扩张剂,给予口服厄贝沙坦75～225mg/d,治疗6周。观察治疗前、后心率、血压、心胸比、左室舒张末期内径、左室射血分数以及心功能的变化。结果:治疗后心率、血压、心胸比及左室舒张末期内径均明显下降(P<0.05、<0.01)。左室射血分数增加(P<0.01),心功能改善1～2级。药物副作用少,患者耐受性好。结论:国产厄贝沙坦治疗CHF疗效好,副作用少,值得推广。     

厄贝沙坦治疗慢性充血性心力衰竭临床研究

对48例慢性充血性心力衰竭（CHF）患者在联合应用利尿剂、血管扩张剂、β受体阻滞剂、洋地黄的基础上,加用厄贝沙坦治疗。治疗后患者心率、心胸比、收缩压、舒张压、左室舒张末期内径、左室射血分数等与治疗前比较均有统计学差异（P〈0．05）。认为厄贝沙坦治疗CHF疗效好、不良反应少、依从性好,可以作为治疗CHF的基本药物。     

缬沙坦联合卡维地洛治疗慢性充血性心力衰竭

目的观察缬沙坦和卡维地洛对慢性充血性心力衰竭(CHF)的临床疗效及安全性。方法将72例CHF患者随机分为两组。对照组应用洋地黄、利尿剂及卡维地洛,治疗组在此基础上加用缬沙坦。观察治疗前后心功能、左室射血分数等。结果两组治疗半年后,治疗组总有效率为97.2%,对照组为83.3%(P0.05)。治疗后观察组左室舒张期末内径显著低于对照组。左室射血分数显著高于对照组(P0.05)。结论缬沙坦和卡维地洛联合治疗可提高疗效,明显改善CHF患者的预后。     

厄贝沙坦与培哚普利联合治疗充血性心力衰竭

目的探讨厄贝沙坦(Ibesartan)与培哚普利(Perindopril)联合治疗充血性心力衰竭(CHF)的疗效.方法 102例CHF病人在应用洋地黄、利尿剂的基础上,随机分为A组(n＝52):口服厄贝沙坦每天75 mg,培哚普利,每日4 mg;B组(n＝50):口服培哚普利每日4 mg.治疗前、后分别进行心功能(NYHA 分级)评估,行血常规、血生化、肝、肾功能、心电图、超声心动图检查.结果治疗8周后两组左房内径(LA)、左室舒张末期容量(LVEDV)、左室收缩末期容量(LVESV)、左心室射血分数(LVEF)、短轴缩短率(FS)、心排血量(CO)、心排血指数(CI)均有显著改善(P<0.05).LVEDV、LVESV、EF、FS及心功能改善总有效率A组与B组比较改善更为显著(P<0.05).两组治疗前、后血生化、肝、肾功能均无显著变化,不良反应发生率相仿(P>0.05).结论厄贝沙坦与培哚普利联合治疗CHF优于单用培哚普利.     

美托洛尔(倍他乐克)治疗慢性充血性心力衰竭

目的　观察美托洛尔 (倍他乐克 )对慢性充血性心力衰竭患者心脏功能和运动耐量的影响。方法　选择慢性充血性心力衰竭患者 6 4例 ,分为扩张型心肌病组和缺血性心肌病组 ,在常规治疗心力衰竭的基础上加用美托洛尔 ,治疗前后观察LVEF、E峰、A峰以及E/A比值、心功能分级和活动平板运动耐量变化。结果　通过以上观察指标证明美托洛尔对扩张型心肌病的疗效优于缺血性心肌病。结论　美托洛尔可对抗心衰患者交感神经对心脏的毒性反应 ,提高心脏功能和运动耐量 ,尤其是对以受体下调为主的扩张型心肌病疗效确切。     

缬沙坦联合倍他乐克治疗慢性充血性心力衰竭的疗效观察

目的探讨研究缬沙坦联合倍他乐克治疗慢性充血性心力衰竭的临床效果。方法选取2013年2月~2014年2月来我院治疗的慢性充血性心力衰竭患者52例,随机分为观察组与对照组,每组26人,对照组实施常规内科治疗,观察组在此基础上实施缬沙坦联合倍他乐克治疗,对两组患者的临床疗效进行比较。结果经治疗后观察组的总有效率为88.5%,明显高于对照组73.1%,差异具有统计学意义(P0.05);治疗后观察组的HR、SBP以及DBP均比对照组降低明显,差异具有统计学意义(P0.05);治疗后观察组的心功能指标LVEF的提高明显高于对照组,并且差异具有统计学意义(P0.05)。结论采用缬沙坦联合倍他乐克治疗慢性充血性心力衰竭效果明显,能够明显改善患者心功能,值得在临床上推广应用。     

DITPA治疗充血性心力衰竭的研究进展

本文就近年来甲状腺激素及DITPA治疗充血性心力衰竭的作用机制、治疗效应等研究作一综述.     

参附注射液联合硝普钠治疗慢性充血性心力衰竭

目的评价硝普钠联合参附注射液对慢性充血性心力衰竭病人的疗效。方法将95例慢性充血性心力衰竭病人随机分为常规治疗组、硝普钠治疗组和参附注射液联合硝普钠治疗组(联合治疗组),观察3组病人治疗前后心率、血压、左室射血分数(LVEF)以及心功能的变化,并进行统计学分析。结果联合治疗组总有效率为96.88%,优于常规治疗组的70.97%与硝普钠治疗组的90.60%(P<0.05)。联合治疗组在降低收缩压、提高LVEF方面作用强于常规治疗组与硝普钠治疗组(P<0.05)。结论硝普钠联合参附注射液治疗能更有效治疗慢性充血性心力衰竭。     

卡维地洛在充血性心力衰竭中的作用

卡维地洛是一种新型的非选择性β受体阻滞剂,许多临床实验证实卡维地洛长期治疗可降低充血性心力衰竭患者死亡率。现对卡维地洛在充血性心力衰竭中的作用进行综述。     

慢性充血性心力衰竭的疑难性和中医药治疗对策

从慢性心力衰竭高死亡率的发病特点,强调该病的严重性,从临床表现的隐袭特征,论述心力衰竭的疑难性.按照其发病过程,从早期、中期、晚期来讨论其发病机制,治疗主要是补虚、开郁、活血、利水.     

慢性充血性心力衰竭的氨基酸疗法研究

目的研究口服L-精氨酸和瓜氨酸对慢性充血性心力衰竭病人内皮功能的影响。方法用光电体积描记术记录30例确诊病人示指脉搏波。测定口服L-精氨酸和瓜氨酸试验前后静息状态下脉搏波和缺血后每30s时间段的最大脉搏波时长、总时长以及两者之间的比值。结果两组受试者试验前脉搏波无明显差异。口服氨基酸后,每30s时间段的最大脉搏波时长/总时长比值较试验前均有显著差异,试验前后静息状态下脉搏波,L-精氨酸组（38.75±11.52 vs 23.32±6.08,P=0.007）和瓜氨酸组（41.4±13.47 vs 23.65±6.74,P=0.007）。试验前后60～90s时间段,L-精氨酸组（36.60±11.51 vs 18.81±15.13,P=0.004）和瓜氨酸组（49.51±15.17 vs 27.13±7.87,P=0.003）。结论 口服L-精氨酸和瓜氨酸有助于改善内皮功能,减低血压和肺动脉收缩压,辅助治疗慢性充血性心力衰竭。     

卡维地洛治疗心力衰竭的疗效观察

目的 观察卡维地洛对充血性心力衰竭(CHF)的临床疗效。方法 将52例CHF患者随机分为卡维地洛组和常规治疗组，卡维地洛组在常规抗心衰治疗的基础上给予卡维地洛；常规治疗组采用安慰剂加常规抗心衰治疗。结果 卡维地洛治疗5个月后心功能及超声指标与常规治疗组相比均明显改善。结论 卡维地洛对充血性心力衰竭的治疗有显著效果。     

参芪扶正注射液对充血性心力衰竭病人血流动力学的影响

目的观察参芪扶正注射液对充血性心力衰竭(CHF)病人血流动力学的影响。方法将60例CHF病人随机分为参芪扶正组和常规治疗组各30例。常规治疗组给予血管紧张素转换酶抑制剂、利尿剂、洋地黄制剂等常规治疗。参芪扶正组在此基础上加用参芪扶正注射液。两组均治疗14d,治疗前后采用超声心动仪测定左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)和左室射血分数(LVEF)。结果治疗后参芪扶正组LVEDD和LVESD分别为(55.16±5.07)mm和(42.27±7.39)mm,显著低于常规治疗组(60.27±6.41)mm和(50.89±8.31)mm(P<0.01);LVEF为49.25%±8.78%,显著高于常规治疗组40.75%±7.43%(P<0.01)。结论参芪扶正注射液可明显改善CHF病人左心室功能。     

Effects of Carvedilol on Heart Rate Dynamics in Patients with Congestive Heart Failure

Background: Patients with congestive heart failure (CHF) have alterations in the traditional and nonlinear indices of heart rate (HR) dynamics, which have been associated with an increased risk of mortality. This study was designed to test the effects of carvedilol, a nonselective beta‐blocker with alpha‐1 blocking properties, on HR dynamics in patients with CHF. Methods: We studied 15 patients with CHF secondary to ischemic or idiopathic cardiomyopathy who met the following inclusion criteria: NYHA functional class II‐III, optimal conventional medical therapy, normal sinus rhythm, left ventricular ejection fraction (LVEF) of < 40%, and resting systolic blood pressure greater than 100 mmHg. The 6‐minute corridor walk test, estimation of LVEF, and 24‐hour Holter recording were performed at baseline and after 12 weeks of therapy with carvedilol. Traditional time and frequency domain measures and short‐term fractal scaling exponent of HR dynamics were analyzed. Results: After 12 weeks of therapy with carvedilol, the mean LVEF improved significantly (from 0.27 ± 0.08 to 0.38 ± 0.08, P < 0.001). The average HR decreased significantly (from 86 ± 11 to 70 ± 8 beats/min, P < 0.001). The mean distance traveled in the 6‐minute walk test increased significantly (from 177 ± 44 to 273 ± 55 m, P < 0.01). The frequency‐domain indices (HF and LF), the time domain indices (rMSSD and PNN5), and the short‐term fractal scaling exponent increased significantly. The scaling exponent increased particularly among the patients with the lowest initial values (< 1.0), and the change in the fractal scaling exponent correlated with the change in ejection fraction (r = 0.63, P < 0.01). Conclusion: Carvedilol improves time and frequency domain indices of HR variability and corrects the altered scaling properties of HR dynamics in patients with CHF. It also improves LVEF and functional capacity. These specific changes in HR behavior caused by carvedilol treatment may reflect the normalization of impaired cardiovascular neural regulation of patients with CHF. A.N.E. 2002;7(2):133–138     

Prenalterol as Long-term Therapy for Chronic Congestive Heart Failure

Abstract Ten patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics were randomly allocated to oral treatment with prenalterol (100–200 mg daily in addition to their basal treatment) or to intensified treatment with diuretics in a cross-over trial. A wash-out period of 1–4 weeks was allowed between the two modes of treatment. Most of the patients demonstrated subjective improvement during prenalterol therapy, but this improvement could not be verified objectively by exercise test, echocardiography, chest X-ray or weight measurements. No serious side-effects of either mode of treatment were observed. Heart rate was significantly lower during exercise when the patients were treated with prenalterol than during the control periods or during intensified conventional treatment, indicating that prenalterol acts as a β-adrenergic receptor blocker during exercise in this patient group. The results indicate that prenalterol is a partial β-receptor agonist without superior beneficial effects compared to those of intensified conventional treatment in patients with chronic, severe CHF.     

The Administration and Effect of Sodium Nitroprusside in the Treatment of Chronic Congestive Heart Failure

To prove the effectiveness and safety of sodium nitroprusside (SNP) in the treatment of chronic congestive heart failure, 58 patients with heart failure and normal renal and hepatic function were selected and divided into 3 groups and treated differently. Group A was treated with routine vasodilators; Group B was treaeted intermittently with SNP (12. 5 -75mg/24hrs); Group C was treated continuously with SNP (continuous infusion of 100 - 300mg/24hrs) Positively inotropie agents and diuretic agents were used in each group. The results showed that the highly effective rates of the three groups were 46. 9% (15/32), 90. 5% (19/21) and 100% (12/12) respectively. The effective rates were 81.3% (26/32), 100% (21/21), 100% (12/12) respectively. The highly effective rates of group B and C were much higher than that of group A ( P < 0. 005, P < 0. 005) . The reduction of blood pressure of group B and C was greater than that of group A ( P < 0. 025) . Among the patients we studied, no body had severe side effects.